|
|
 |
|
 |
|
|
|
|
|
|
|
|
|
Mission
With unsurpassed commitment and energy, Pharmalucence will support the advancement
of human healthcare via:
- the ongoing development and supply of
molecular imaging agents;
- the delivery of specialized contract
services that enable the development, manufacture and commercialization of new
parenteral drugs by our biopharmaceutical industry clients.
|
|
|
|
| |
|
|
Quality
|
|
| |
|
|
Pharmalucence operates under a comprehensive Quality Management System to ensure
compliance with a variety of regulatory and customer requirements and standards,
which include but are not limited to the following:
cGMP/QSR (21 CFR 210, 211, 820)
EN ISO 13485:2003
ISO 13485:2003 / CMDCAS
NRC
DOT
OSHA
Pharmalucence maintains product and service excellence through its commitment to
quality standards developed to meet or exceed the needs of our customers. All
Pharmalucence employees actively participate in and contribute to a quality oriented
environment focused on continuous improvement.
|
| BACK TO TOP |
|
|
History
|
|
| |
|
|
Pharmalucence traces its roots to CIS-US, Inc., the U. S. subsidiary of CIS bio
international, itself an asset of CEA headquartered in Paris, France. CIS-US was
incorporated in 1985 to commercialize medical applications derived from isotopic
technologies developed by its French ownership. In the late 1980’s, the company
acquired a production facility in Bedford, MA, establishing itself as a U. S. manufacturer
of radiopharmaceuticals and medical devices.
Between 1999 and 2007, CIS-US passed through three ownership changes, culminating
in an employee privatization.
- 2000 – sold by CEA to Schering AG, Berlin.
- 2006 – sold by Schering AG to IRE/IBA Molecular.
- 2007 – sold by IRE/IBA Molecular to CIS-US employee-based partnership thus establishing
Pharmalucence, Inc.
|
| BACK TO TOP |
|
|
Company Overview
|
|
| |
|
|
Pharmalucence – we are reinforcing our position as a
leader in the supply of radiopharmaceuticals through the development and launch of new
products to support the needs of nuclear medicine practitioners and their radiopharmacy
affiliates.
Pharmalucence – we are expanding our contract services
to include process development to complement our clinical and commercial drug production
service.
Pharmalucence – we are committed to maintaining
trouble-free operation of the many IBL 437C Blood Irradiator systems installed in
hospitals and commercial blood banks throughout the U.S. via our factory trained field
service engineering team.
|
| BACK TO TOP |
|
|
|
|
|
|
|
|
| Created by Red Brick Design |
|
|
|
